Adding Pirtobrutinib to Venetoclax-Rituximab Shows Significant Improvement in PFS Among Patients with Previously Treated CLL By Ogkologos - August 6, 2026 100 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the BRUIN CLL-322 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Welcomes the European Parliament’s (EP) Call for a Sustainable Cancer Workforce to Deliver Quality Care for Patients with Cancer ESMO Welcomes the Inclusion of Tobacco Provisions in European Parliament’s Report on Cardiovascular Diseases and Calls for Additional Measures to Prevent Cancer Perioperative Durvalumab Continues to Show Clinical Benefit in Patients with Resectable Stage IIA to IIIB NSCLC MOST POPULAR Countdown to 100,000 OncoLife Survivorship Care Plans: How it all started February 19, 2021 New Imaging Tool Could Predict Whether Hormone Therapy Will Work in... February 4, 2021 Using a Mind-Body Connection to Help You Cope During Cancer: An... January 11, 2024 Study Shows that Disrupted Gut Bacteria May Contribute to the Spread... June 21, 2019 Load more HOT NEWS Stopping neuropathy: One of chemotherapy’s most challenging side effects ESMO Congresses in March: Sarcoma and Rare Cancers Congress and European... Olaparib after Initial Treatment Delays Ovarian Cancer Progression Longitudinal Profiling of the Gut Microbiome in Patients Undergoing Immune Checkpoint...
